{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:07:54Z","timestamp":1790798874228,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jdcr.2022.01.029","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T11:58:37Z","timestamp":1644494317000},"page":"31-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Can\u2019t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab"],"prefix":"10.1016","volume":"22","author":[{"given":"Eva","family":"Shelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coley","family":"Doolittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi M.","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata S.","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdcr.2022.01.029_bib1","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.0901860","article-title":"IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation","volume":"184","author":"Sehra","year":"2010","journal-title":"J Immunol"},{"issue":"115","key":"10.1016\/j.jdcr.2022.01.029_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1183\/09059180.00007609","article-title":"Investigational therapeutics targeting the IL-4\/IL-13\/STAT-6 pathway for the treatment of asthma","volume":"19","author":"Oh","year":"2010","journal-title":"Eur Respir Rev"},{"issue":"11","key":"10.1016\/j.jdcr.2022.01.029_bib3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.36849\/JDD.2020.5648","article-title":"Grover disease associated with chemotherapy: Review of potential pathophysiology, current treatments, and future directions","volume":"19","author":"Beer","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2022.01.029_bib4","doi-asserted-by":"crossref","DOI":"10.5070\/D3262047431","article-title":"Transient acantholytic dermatosis in a patient with prostate cancer","volume":"26","author":"Khan","year":"2020","journal-title":"Dermatol Online J"},{"issue":"10","key":"10.1016\/j.jdcr.2022.01.029_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10.1016\/j.jdcr.2022.01.029_bib6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bjd.13058","article-title":"First report of ipilimumab-induced Grover disease","volume":"171","author":"Munoz","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2022.01.029_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer","volume":"8","author":"Hardy-Werbin","year":"2019","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.jdcr.2022.01.029_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jdcr.2022.01.029_bib9","article-title":"Dupilumab in dermatology: Potential for uses beyond atopic dermatitis","volume":"18","author":"Maloney","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.01.029_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13190","article-title":"Targeting interleukin 4 receptor \u03b1: A new approach to the treatment of cutaneous autoimmune bullous diseases?","volume":"33","author":"Russo","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdcr.2022.01.029_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2015.10.036","article-title":"Mast cells and eosinophils in allergy: Close friends or just neighbors","volume":"778","author":"Gangwar","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.jdcr.2022.01.029_bib12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1523-1747.2002.01753.x","article-title":"Overexpression of IL-4 alters the homeostasis in the skin","volume":"118","author":"Elbe-B\u00fcrger","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.01.029_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1046\/j.0022-202x.2001.01484.x","article-title":"Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis","volume":"117","author":"Chan","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.01.029_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/ejd.2018.3366","article-title":"Immunoglobulin E and bullous pemphigoid","volume":"28","author":"Cozzani","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.01.029_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on Atopic dermatitis: Diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jdcr.2022.01.029_bib16","first-page":"534","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2022.01.029_bib17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.01.029_bib18","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1111\/pde.13533","article-title":"Eosinophilic annular erythema treated with dupilumab","volume":"35","author":"Gordon","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2022.01.029_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamadermatol.2020.5097","article-title":"Treatment of Grover disease with dupilumab","volume":"157","author":"Butler","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:04Z","timestamp":1762475044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":19,"alternative-id":["S2352512622000753"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.01.029","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can\u2019t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}